<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01703507</url>
  </required_header>
  <id_info>
    <org_study_id>12P.314</org_study_id>
    <secondary_id>2012-43</secondary_id>
    <nct_id>NCT01703507</nct_id>
  </id_info>
  <brief_title>Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma</brief_title>
  <official_title>Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients With Brain Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Cancer Center at Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and best dose of ipilimumab when given together
      with whole brain radiation therapy or stereotactic radiosurgery in treating patients with
      melanoma with brain metastases. Monoclonal antibodies, such as ipilimumab, can block tumor
      growth in different ways. Some block the ability of the tumor to grow and spread. Others find
      Tumor cells and help kill them or carry tumor-killing substances to them. Radiation therapy,
      such uses high-energy x-rays and other types of radiation to kill tumor cells. Giving
      radiation therapy in different ways may kill more tumor cells. Giving ipilimumab together
      with whole-brain radiation therapy or stereotactic radiosurgery may kill more tumor cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Melanoma patients with brain metastases have a very poor outcome. Most patients with brain
      metastases will die from CNS related death. Radiation therapy is an effective treatment for
      patients with brain metastases for symptom palliation and survival benefit. Patients with
      multiple metastases are typically treated with whole brain radiation treatment (WBRT). For
      patients with a few metastases, stereotactic radiosurgery (SRS) alone can be used as an
      alternative. CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4) antibody, Ipilimumab has shown
      efficacy in metastatic melanoma and unresectable melanoma. Treatment with high doses of
      radiation therapy would result in tumor cell death, releasing tumor debris and liberating
      potential tumor antigens. We hypothesize that combining radiation therapy with Ipilimumab
      will facilitate immune recognition of these novel tumor-specific antigens, yielding a
      synergistic effect. Further, the hypothesis of this study is that this combination could
      focus the immune system on tumor antigens and minimize the aberrant immune activation in
      normal tissues, consequently reducing the incidence of irAE's (immune related adverse
      effect). Combination of radiation treatment with Ipilimumab will likely result in better
      local control, decrease the risk of developing new brain metastases, and improved overall
      survival. However, the safety profile and toxicities of combining Ipilimumab with brain
      radiation treatment are unknown. The current phase I study will assess the safety profile of
      combining different doses of Ipilimumab with standard dose radiation treatment either with
      WBRT or SRS. The MTD (maximum tolerated dose) will be determined, as well as a recommended
      phase II trial dose of Ipilimumab.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 9, 2012</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Actual">May 20, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of ipilimumab</measure>
    <time_frame>30 days following the completion of radiation therapy</time_frame>
    <description>(MTD) when combined with WBRT or SRS, defined as the last dose studied or the previous dose, based on clinical judgment of the degree of toxicity seen at the last dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of developing new brain metastases in each arm</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response of extracranial disease</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) rate</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) rate</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>PFS rate based on Response Evaluation Criteria in Solid Tumors (RECIST) and immune-related response criteria (irRC) criteria based on the brain MRI and systematic assessment by the treating physician</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability in terms of adverse events and serious adverse events</measure>
    <time_frame>4 weeks following the last dose of ipilimumab</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Recurrent Melanoma</condition>
  <condition>Stage IV Melanoma</condition>
  <condition>Tumors Metastatic to Brain</condition>
  <arm_group>
    <arm_group_label>Arm A (Ipilimumab and Whole Brain Radiation Therapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive ipilimumab IV over 90 minutes once in weeks 1, 4, 7, and 10. Patients also undergo WBRT 5 days a week in weeks 1-2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (Ipilimumab and Stereotactic Radiosurgery)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive ipilimumab IV over 90 minutes as in Arm A. Patients also undergo SRS on day 1 in week 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (Ipilimumab and Whole Brain Radiation Therapy)</arm_group_label>
    <arm_group_label>Arm B (Ipilimumab and Stereotactic Radiosurgery)</arm_group_label>
    <other_name>MDX-010</other_name>
    <other_name>MDX-101</other_name>
    <other_name>Yervoy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Whole-Brain Radiation Therapy (WBRT)</intervention_name>
    <description>Undergo WBRT</description>
    <arm_group_label>Arm A (Ipilimumab and Whole Brain Radiation Therapy)</arm_group_label>
    <other_name>WBRT</other_name>
    <other_name>Whole-brain radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Radiosurgery (SRS)</intervention_name>
    <description>Undergo SRS</description>
    <arm_group_label>Arm B (Ipilimumab and Stereotactic Radiosurgery)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient age is &gt;= 18 years

          2. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0, or
             1.

          3. Ability to provide written informed consent obtained prior to participation in the
             study and any related procedures being performed

          4. Patients must meet the following laboratory criteria:

               -  WBC &gt;= 2000/uL

               -  ANC &gt;= 1000/uL

               -  Platelets &gt;= 75 x 10^3/uL

               -  Hemoglobin &gt;= 9 g/dL (&gt;= 80 g/L; may be transfused)

               -  AST/ALT &lt;= 2.5 x ULN for patients without liver metastasis

               -  AST/ALT &lt;= 5 times for liver metastases

               -  Bilirubin &lt;= 2.0 x ULN, (except patients with Gilbert's Syndrome, who must have a
                  total bilirubin less than 3.0 mg/dL)

               -  Serum creatinine &lt;= 2.0 x ULN or 24-hour creatinine clearance &gt;= 50 ml/min

               -  Total serum calcium (corrected for serum albumin) or ionized calcium &gt;= lower
                  limit of normal (LLN)

               -  Serum potassium &gt;= LLN

               -  Serum sodium &gt;= LLN

               -  Serum albumin &gt;= LLN or 3g/dl

               -  Patients with any elevated Alkaline Phosphatase due to bone metastases can be
                  enrolled

          5. No active or chronic infection with HIV, Hepatitis B, or Hepatitis C.

          6. Clinically euthyroid. Note: Patients are permitted to receive thyroid hormone
             supplements to treat underlying hypothyroidism.

          7. Women of childbearing potential (WOCBP) must be using an adequate method of
             contraception to avoid pregnancy throughout the study and for up to 26 weeks after the
             last dose of investigational product, in such a manner that the risk of pregnancy is
             minimized. WOCBP include any female who has experienced menarche and who has not
             undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation,
             or bilateral oophorectomy) or is not post-menopausal. Post-menopause is defined as:

               -  Amenorrhea &gt;= 12 consecutive months without another cause, or

               -  For women with irregular menstrual periods and taking hormone replacement therapy
                  (HRT), a documented serum follicle stimulating hormone (FSH) level &gt;= 35 mIU/mL.

               -  Women who are using oral contraceptives, other hormonal contraceptives (vaginal
                  products, skin patches, or implanted or injectable products), or mechanical
                  products such as an intrauterine device or barrier methods (diaphragm, condoms,
                  spermicides) to prevent pregnancy, or are practicing abstinence or where their
                  partner is sterile (eg, vasectomy) should be considered to be of childbearing
                  potential.

               -  WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25
                  IU/L or equivalent units of HCG) within 72 hours before the start of ipilimumab.

          8. Men of fathering potential must be using an adequate method of contraception to avoid
             conception throughout the study (and for up to 26 weeks after the last dose of
             investigational product) in such a manner that the risk of pregnancy is minimized.

          9. A pathological diagnosis of melanoma is required, from either the primary or a
             metastasis. This also includes uveal melanoma.

         10. A radiological diagnosis (CT or MRI) of one or more brain metastases is required.

         11. Resolution of all acute toxic effects of prior chemotherapy or radiotherapy or
             surgical procedures to NCI CTCAE Version 4.0 grade &lt;= 1.

         12. Specific eligibility criteria for the two arms

               -  Arm A WBRT and Ipilimumab:

                    -  Patients have 5 or more brain metastases, or patients have any brain
                       metastases exceeding the limit for SRS (maximum diameter is &gt; 4 cm).

                    -  OR Patient has only one brain metastasis and completely resected, the
                       resection cavity is &gt; 4 cm in diameter.

               -  Arm B SRS and Ipilimumab:

                    -  Patients have 4 or fewer brain metastases. All the brain metastases are &lt;= 4
                       cm in diameter.

                    -  Patients have only one brain metastasis and completely resected, the
                       resection cavity is &lt;= 4 cm in diameter.

                    -  OR If a patient is found to have progression of brain metastases that exceed
                       4 cm in diameter based on the MRI scan on the time of SRS procedure, the
                       patient should be re-assigned to WBRT arm or withdrawn from the study. The
                       study PI should be notified.

                    -  OR If a patient is found to have progression of brain metastases that exceed
                       4 lesions based on the MRI scan on the time of the SRS procedure, the
                       patient can either be treated with SRS to all the lesions (up to 10
                       lesions), re-assigned to WBRT arm, or withdrawn from the study per the
                       treating physician. The study PI should be notified.

        Exclusion Criteria:

          1. Patient with leptomeningeal carcinomatosis.

          2. Autoimmune disease: Patients with a history of inflammatory bowel disease, including
             ulcerative colitis and Crohn's Disease, are excluded from this study, as are patients
             with a history of symptomatic disease (eg, rheumatoid arthritis, systemic progressive
             sclerosis [scleroderma], systemic lupus erythematosus, autoimmune vasculitis [eg,
             Wegener's Granulomatosis]); motor neuropathy considered of autoimmune origin (e.g.
             Guillain-Barre Syndrome and Myasthenia Gravis).

          3. Major surgery or radiation therapy within 2 weeks of starting the study treatment.

          4. If patients are receiving chemotherapy or other investigational drugs, they must be
             discontinued 4 weeks prior to enrollment.

          5. NCI CTCAE grade 3 hemorrhage within 4 weeks of starting the study treatment.

          6. Any of the following within the 6 months prior to study drug administration:

             myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass
             graft, symptomatic congestive heart failure, cerebrovascular accident or transient
             ischemic attack, or pulmonary embolism. Patients with known cardiac disease will be
             required to have an ECHO or MUGA scan at baseline and at the completion of study.

          7. Ongoing cardiac dysrhythmias of NCI CTCAE grade &gt;= 2.

          8. Hypertension that cannot be controlled by medications (&gt;150/100 mm Hg despite optimal
             medical therapy).

          9. Pre-existing thyroid abnormality with thyroid function that cannot be maintained in
             the normal range with medication.

         10. Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome
             (AIDS)-related illness or other active infection.

         11. Pregnancy or breastfeeding. Female subjects must be surgically sterile or be
             postmenopausal, or must agree to use effective contraception during the period of
             therapy. All female subjects with reproductive potential must have a negative
             pregnancy test (serum or urine) prior to enrollment. Male subjects must be surgically
             sterile or must agree to use effective contraception during the period of therapy. The
             definition of effective contraception will be based on the judgment of the principal
             investigator or a designated associate.

         12. Other severe acute or chronic medical or psychiatric condition or laboratory
             abnormality that may increase the risk associated with study participation or study
             drug administration, or may interfere with the interpretation of study results, and in
             the judgment of the investigator would make the subject inappropriate for entry into
             this study.

         13. Concomitant therapy with any of the following: IL-2, interferon, or other non-study
             immunotherapy regimens, cytotoxic chemotherapy, immunosuppressive agents,
             vermurafenib, or other investigational therapies.

         14. All efforts need to be taken to avoid/minimize the use of cortical steroid during
             radiation period (1 week prior to start radiation, during radiation, and 1 week after
             finishing radiation). Any steroid used considered necessary by the treating physician
             should be closely documented, including medication, route of administration, dose, and
             duration.

         15. Active infection with hepatitis B, or hepatitis C.

         16. Patients who had prior brain radiation treatment.

         17. Patients are excluded if they have a history of any other malignancy from which the
             patient has been disease-free for less than 2 years, with the exception of adequately
             treated basal or squamous cell carcinoma of skin, superficial bladder cancer or
             carcinoma in situ of cervix, AJCC (version 7.0) stage 0 or I breast cancer, AJCC
             (version 7.0) stage I, or II prostate cancer.

         18. Patients are excluded if they have a history of autoimmune disease, as follows:
             Patients with a history of inflammatory bowel disease are excluded from this study as
             are patients with a history of symptomatic disease (e.g., rheumatoid arthritis,
             systemic progressive sclerosis [scleroderma], Systemic Lupus Erythematosus, autoimmune
             vasculitis [e.g., Wegener's Granulomatosis]). Patients with motor neuropathy
             considered of autoimmune origin (e.g., Guillain-Barre Syndrome and Myasthenia Gravis)
             are excluded. Patients with a history of autoimmune thyroiditis are eligible if their
             current thyroid disorder is treated and stable with replacement or other medical
             therapy.

         19. Patients who are allergic to Ipilimumab.

         20. Patients who received ipilimumab before.

         21. Patients who are allergic to MRI contrast agent or have contraindication for MRI.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wenyin Shi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.KimmelCancerCenter.org</url>
    <description>Kimmel Cancer Center at Thomas Jefferson University, an NCI-Designated Cancer Center</description>
  </link>
  <link>
    <url>http://www.JeffersonHospital.org</url>
    <description>Thomas Jefferson University Hospitals</description>
  </link>
  <reference>
    <citation>Bafaloukos D, Gogas H. The treatment of brain metastases in melanoma patients. Cancer Treat Rev. 2004 Oct;30(6):515-20. Review.</citation>
    <PMID>15325032</PMID>
  </reference>
  <reference>
    <citation>Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg. 1995 Sep;181(3):193-201.</citation>
    <PMID>7670677</PMID>
  </reference>
  <reference>
    <citation>Sampson JH, Carter JH Jr, Friedman AH, Seigler HF. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg. 1998 Jan;88(1):11-20.</citation>
    <PMID>9420067</PMID>
  </reference>
  <reference>
    <citation>Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ, Markesbery WR, Foon KA, Young B. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA. 1998 Nov 4;280(17):1485-9.</citation>
    <PMID>9809728</PMID>
  </reference>
  <reference>
    <citation>Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, Markesbery WR, Macdonald JS, Young B. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990 Feb 22;322(8):494-500.</citation>
    <PMID>2405271</PMID>
  </reference>
  <reference>
    <citation>Andrews DW. Current neurosurgical management of brain metastases. Semin Oncol. 2008 Apr;35(2):100-7. doi: 10.1053/j.seminoncol.2007.12.003. Review.</citation>
    <PMID>18396195</PMID>
  </reference>
  <reference>
    <citation>Thomas SS, Dunbar EM. Modern multidisciplinary management of brain metastases. Curr Oncol Rep. 2010 Jan;12(1):34-40. doi: 10.1007/s11912-009-0073-8. Review.</citation>
    <PMID>20425606</PMID>
  </reference>
  <reference>
    <citation>CHU FC, HILARIS BB. Value of radiation theray in the management of intracranial metastases. Cancer. 1961 May-Jun;14:577-81.</citation>
    <PMID>13693470</PMID>
  </reference>
  <reference>
    <citation>Expert Panel on Radiation Oncology-Brain Metastases, Videtic GM, Gaspar LE, Aref AM, Germano IM, Goldsmith BJ, Imperato JP, Marcus KJ, McDermott MW, McDonald MW, Patchell RA, Robins HI, Rogers CL, Suh JH, Wolfson AH, Wippold FJ 2nd. American College of Radiology appropriateness criteria on multiple brain metastases. Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):961-5. doi: 10.1016/j.ijrobp.2009.07.1720.</citation>
    <PMID>19857783</PMID>
  </reference>
  <reference>
    <citation>DiLuna ML, King JT Jr, Knisely JP, Chiang VL. Prognostic factors for survival after stereotactic radiosurgery vary with the number of cerebral metastases. Cancer. 2007 Jan 1;109(1):135-45.</citation>
    <PMID>17133440</PMID>
  </reference>
  <reference>
    <citation>Manon R, O'Neill A, Knisely J, Werner-Wasik M, Lazarus HM, Wagner H, Gilbert M, Mehta M; Eastern Cooperative Oncology Group. Phase II trial of radiosurgery for one to three newly diagnosed brain metastases from renal cell carcinoma, melanoma, and sarcoma: an Eastern Cooperative Oncology Group study (E 6397). J Clin Oncol. 2005 Dec 1;23(34):8870-6.</citation>
    <PMID>16314647</PMID>
  </reference>
  <reference>
    <citation>Mathieu D, Kondziolka D, Cooper PB, Flickinger JC, Niranjan A, Agarwala S, Kirkwood J, Lunsford LD. Gamma knife radiosurgery for malignant melanoma brain metastases. Clin Neurosurg. 2007;54:241-7.</citation>
    <PMID>18504926</PMID>
  </reference>
  <reference>
    <citation>Clarke JW, Register S, McGregor JM, Grecula JC, Mayr NA, Wang JZ, Li K, Gupta N, Kendra KL, Olencki TE, Cavaliere R, Sarkar A, Lo SS. Stereotactic radiosurgery with or without whole brain radiotherapy for patients with a single radioresistant brain metastasis. Am J Clin Oncol. 2010 Feb;33(1):70-4. doi: 10.1097/COC.0b013e31819ccc8c.</citation>
    <PMID>19652578</PMID>
  </reference>
  <reference>
    <citation>Order SE, Hellman S, Von Essen CF, Kligerman MM. Improvement in quality of survival following whole-brain irradiation for brain metastasis. Radiology. 1968 Jul;91(1):149-53.</citation>
    <PMID>4172540</PMID>
  </reference>
  <reference>
    <citation>Khuntia D, Brown P, Li J, Mehta MP. Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol. 2006 Mar 10;24(8):1295-304. Review.</citation>
    <PMID>16525185</PMID>
  </reference>
  <reference>
    <citation>Patchell RA, Regine WF. The rationale for adjuvant whole brain radiation therapy with radiosurgery in the treatment of single brain metastases. Technol Cancer Res Treat. 2003 Apr;2(2):111-5. Review.</citation>
    <PMID>12680791</PMID>
  </reference>
  <reference>
    <citation>Borgelt B, Gelber R, Larson M, Hendrickson F, Griffin T, Roth R. Ultra-rapid high dose irradiation schedules for the palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1981 Dec;7(12):1633-8.</citation>
    <PMID>6174490</PMID>
  </reference>
  <reference>
    <citation>Chatani M, Matayoshi Y, Masaki N, Inoue T. Radiation therapy for brain metastases from lung carcinoma. Prospective randomized trial according to the level of lactate dehydrogenase. Strahlenther Onkol. 1994 Mar;170(3):155-61.</citation>
    <PMID>8160096</PMID>
  </reference>
  <reference>
    <citation>Haie-Meder C, Pellae-Cosset B, Laplanche A, Lagrange JL, Tuchais C, Nogues C, Arriagada R. Results of a randomized clinical trial comparing two radiation schedules in the palliative treatment of brain metastases. Radiother Oncol. 1993 Feb;26(2):111-6.</citation>
    <PMID>7681997</PMID>
  </reference>
  <reference>
    <citation>Harwood AR, Simson WJ. Radiation therapy of cerebral metastases: a randomized prospective clinical trial. Int J Radiat Oncol Biol Phys. 1977 Nov-Dec;2(11-12):1091-4.</citation>
    <PMID>74375</PMID>
  </reference>
  <reference>
    <citation>Kurtz JM, Gelber R, Brady LW, Carella RJ, Cooper JS. The palliation of brain metastases in a favorable patient population: a randomized clinical trial by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1981 Jul;7(7):891-5.</citation>
    <PMID>6171553</PMID>
  </reference>
  <reference>
    <citation>Murray KJ, Scott C, Greenberg HM, Emami B, Seider M, Vora NL, Olson C, Whitton A, Movsas B, Curran W. A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: a report of the Radiation Therapy Oncology Group (RTOG) 9104. Int J Radiat Oncol Biol Phys. 1997 Oct 1;39(3):571-4.</citation>
    <PMID>9336134</PMID>
  </reference>
  <reference>
    <citation>Davey P, Hoegler D, Ennis M, Smith J. A phase III study of accelerated versus conventional hypofractionated whole brain irradiation in patients of good performance status with brain metastases not suitable for surgical excision. Radiother Oncol. 2008 Aug;88(2):173-6. doi: 10.1016/j.radonc.2008.05.020. Epub 2008 Jun 12.</citation>
    <PMID>18555546</PMID>
  </reference>
  <reference>
    <citation>Mehta MP, Tsao MN, Whelan TJ, Morris DE, Hayman JA, Flickinger JC, Mills M, Rogers CL, Souhami L. The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):37-46. Review.</citation>
    <PMID>16111570</PMID>
  </reference>
  <reference>
    <citation>Meyners T, Heisterkamp C, Kueter JD, Veninga T, Stalpers LJ, Schild SE, Rades D. Prognostic factors for outcomes after whole-brain irradiation of brain metastases from relatively radioresistant tumors: a retrospective analysis. BMC Cancer. 2010 Oct 26;10:582. doi: 10.1186/1471-2407-10-582.</citation>
    <PMID>20977700</PMID>
  </reference>
  <reference>
    <citation>Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, Werner-Wasik M, Demas W, Ryu J, Bahary JP, Souhami L, Rotman M, Mehta MP, Curran WJ Jr. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004 May 22;363(9422):1665-72.</citation>
    <PMID>15158627</PMID>
  </reference>
  <reference>
    <citation>Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, Kenjyo M, Oya N, Hirota S, Shioura H, Kunieda E, Inomata T, Hayakawa K, Katoh N, Kobashi G. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 2006 Jun 7;295(21):2483-91.</citation>
    <PMID>16757720</PMID>
  </reference>
  <reference>
    <citation>Pirzkall A, Debus J, Lohr F, Fuss M, Rhein B, Engenhart-Cabillic R, Wannenmacher M. Radiosurgery alone or in combination with whole-brain radiotherapy for brain metastases. J Clin Oncol. 1998 Nov;16(11):3563-9.</citation>
    <PMID>9817276</PMID>
  </reference>
  <reference>
    <citation>Sheehan JP, Sun MH, Kondziolka D, Flickinger J, Lunsford LD. Radiosurgery in patients with renal cell carcinoma metastasis to the brain: long-term outcomes and prognostic factors influencing survival and local tumor control. J Neurosurg. 2003 Feb;98(2):342-9.</citation>
    <PMID>12593621</PMID>
  </reference>
  <reference>
    <citation>Powell JW, Chung CT, Shah HR, Canute GW, Hodge CJ, Bassano DA, Liu L, Mitchell L, Hahn SS. Gamma Knife surgery in the management of radioresistant brain metastases in high-risk patients with melanoma, renal cell carcinoma, and sarcoma. J Neurosurg. 2008 Dec;109 Suppl:122-8. doi: 10.3171/JNS/2008/109/12/S19.</citation>
    <PMID>19123898</PMID>
  </reference>
  <reference>
    <citation>Lo SS, Clarke JW, Grecula JC, McGregor JM, Mayr NA, Cavaliere R, Kendra KL, Gupta N, Wang JZ, Sarkar A, Olencki TE. Stereotactic radiosurgery alone for patients with 1-4 radioresistant brain metastases. Med Oncol. 2011 Dec;28 Suppl 1:S439-44. doi: 10.1007/s12032-010-9670-5. Epub 2010 Sep 3.</citation>
    <PMID>20814764</PMID>
  </reference>
  <reference>
    <citation>Nagorsen D, Scheibenbogen C, Marincola FM, Letsch A, Keilholz U. Natural T cell immunity against cancer. Clin Cancer Res. 2003 Oct 1;9(12):4296-303. Review.</citation>
    <PMID>14555498</PMID>
  </reference>
  <reference>
    <citation>Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer. 1996 Apr 1;77(7):1303-10.</citation>
    <PMID>8608507</PMID>
  </reference>
  <reference>
    <citation>Håkansson A, Gustafsson B, Krysander L, Håkansson L. Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment. Br J Cancer. 1996 Sep;74(5):670-6.</citation>
    <PMID>8845294</PMID>
  </reference>
  <reference>
    <citation>Mihm MC Jr, Clemente CG, Cascinelli N. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Invest. 1996 Jan;74(1):43-7.</citation>
    <PMID>8569196</PMID>
  </reference>
  <reference>
    <citation>Moschos SJ, Edington HD, Land SR, Rao UN, Jukic D, Shipe-Spotloe J, Kirkwood JM. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol. 2006 Jul 1;24(19):3164-71.</citation>
    <PMID>16809739</PMID>
  </reference>
  <reference>
    <citation>Peggs KS, Quezada SA, Korman AJ, Allison JP. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol. 2006 Apr;18(2):206-13. Epub 2006 Feb 7. Review.</citation>
    <PMID>16464564</PMID>
  </reference>
  <reference>
    <citation>Tarhini AA, Iqbal F. CTLA-4 blockade: therapeutic potential in cancer treatments. Onco Targets Ther. 2010 Jun 24;3:15-25.</citation>
    <PMID>20616954</PMID>
  </reference>
  <reference>
    <citation>Robert C, Ghiringhelli F. What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma? Oncologist. 2009 Aug;14(8):848-61. doi: 10.1634/theoncologist.2009-0028. Epub 2009 Aug 1. Review.</citation>
    <PMID>19648604</PMID>
  </reference>
  <reference>
    <citation>Read S, Malmström V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med. 2000 Jul 17;192(2):295-302.</citation>
    <PMID>10899916</PMID>
  </reference>
  <reference>
    <citation>Kaehler KC, Piel S, Livingstone E, Schilling B, Hauschild A, Schadendorf D. Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management. Semin Oncol. 2010 Oct;37(5):485-98. doi: 10.1053/j.seminoncol.2010.09.003. Review. Erratum in: Semin Oncol. 2012 Oct;39(5):625.</citation>
    <PMID>21074064</PMID>
  </reference>
  <reference>
    <citation>Morse MA. Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb. Curr Opin Mol Ther. 2005 Dec;7(6):588-97.</citation>
    <PMID>16370382</PMID>
  </reference>
  <reference>
    <citation>Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010 Aug 19;363(8):711-23. doi: 10.1056/NEJMoa1003466. Epub 2010 Jun 5. Erratum in: N Engl J Med. 2010 Sep 23;363(13):1290.</citation>
    <PMID>20525992</PMID>
  </reference>
  <reference>
    <citation>Weber JS, O'Day S, Urba W, Powderly J, Nichol G, Yellin M, Snively J, Hersh E. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol. 2008 Dec 20;26(36):5950-6. doi: 10.1200/JCO.2008.16.1927. Epub 2008 Nov 17.</citation>
    <PMID>19018089</PMID>
  </reference>
  <reference>
    <citation>Schartz NE, Farges C, Madelaine I, Bruzzoni H, Calvo F, Hoos A, Lebbé C. Complete regression of a previously untreated melanoma brain metastasis with ipilimumab. Melanoma Res. 2010 Jun;20(3):247-50. doi: 10.1097/CMR.0b013e3283364a37.</citation>
    <PMID>20216240</PMID>
  </reference>
  <reference>
    <citation>Hodi FS, Oble DA, Drappatz J, Velazquez EF, Ramaiya N, Ramakrishna N, Day AL, Kruse A, Mac Rae S, Hoos A, Mihm M. CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nat Clin Pract Oncol. 2008 Sep;5(9):557-61. doi: 10.1038/ncponc1183. Epub 2008 Jul 29.</citation>
    <PMID>18665147</PMID>
  </reference>
  <reference>
    <citation>Pilones KA, Kawashima N, Yang AM, Babb JS, Formenti SC, Demaria S. Invariant natural killer T cells regulate breast cancer response to radiation and CTLA-4 blockade. Clin Cancer Res. 2009 Jan 15;15(2):597-606. doi: 10.1158/1078-0432.CCR-08-1277.</citation>
    <PMID>19147765</PMID>
  </reference>
  <reference>
    <citation>Jaber SH, Cowen EW, Haworth LR, Booher SL, Berman DM, Rosenberg SA, Hwang ST. Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent. Arch Dermatol. 2006 Feb;142(2):166-72.</citation>
    <PMID>16490844</PMID>
  </reference>
  <reference>
    <citation>Robinson MR, Chan CC, Yang JC, Rubin BI, Gracia GJ, Sen HN, Csaky KG, Rosenberg SA. Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. J Immunother. 2004 Nov-Dec;27(6):478-9.</citation>
    <PMID>15534492</PMID>
  </reference>
  <reference>
    <citation>Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, Macrae S, Nelson M, Canning C, Lowy I, Korman A, Lautz D, Russell S, Jaklitsch MT, Ramaiya N, Chen TC, Neuberg D, Allison JP, Mihm MC, Dranoff G. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3005-10. doi: 10.1073/pnas.0712237105. Epub 2008 Feb 19.</citation>
    <PMID>18287062</PMID>
  </reference>
  <reference>
    <citation>Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Allen TE, Levy CL, Yellin M, Nichol G, White DE, Steinberg SM, Rosenberg SA. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6681-8. Epub 2007 Nov 2.</citation>
    <PMID>17982122</PMID>
  </reference>
  <reference>
    <citation>Korn EL, Liu PY, Lee SJ, Chapman JA, Niedzwiecki D, Suman VJ, Moon J, Sondak VK, Atkins MB, Eisenhauer EA, Parulekar W, Markovic SN, Saxman S, Kirkwood JM. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008 Feb 1;26(4):527-34. doi: 10.1200/JCO.2007.12.7837.</citation>
    <PMID>18235113</PMID>
  </reference>
  <reference>
    <citation>Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, Begg CB, Agarwala SS, Schuchter LM, Ernstoff MS, Houghton AN, Kirkwood JM. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999 Sep;17(9):2745-51.</citation>
    <PMID>10561349</PMID>
  </reference>
  <reference>
    <citation>Middleton MR, Lorigan P, Owen J, Ashcroft L, Lee SM, Harper P, Thatcher N. A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. Br J Cancer. 2000 Mar;82(6):1158-62.</citation>
    <PMID>10735499</PMID>
  </reference>
  <reference>
    <citation>Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, Pavlick AC, DeConti R, Hersh EM, Hersey P, Kirkwood JM, Haluska FG; Oblimersen Melanoma Study Group. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol. 2006 Oct 10;24(29):4738-45. Epub 2006 Sep 11.</citation>
    <PMID>16966688</PMID>
  </reference>
  <reference>
    <citation>van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med. 1999 Aug 2;190(3):355-66.</citation>
    <PMID>10430624</PMID>
  </reference>
  <reference>
    <citation>Suh JH, Videtic GM, Aref AM, Germano I, Goldsmith BJ, Imperato JP, Marcus KJ, McDermott MW, McDonald MW, Patchell RA, Robins HI, Rogers CL, Wolfson AH, Wippold FJ 2nd, Gaspar LE. ACR Appropriateness Criteria: single brain metastasis. Curr Probl Cancer. 2010 May-Jun;34(3):162-74. doi: 10.1016/j.currproblcancer.2010.04.003. Review.</citation>
    <PMID>20541055</PMID>
  </reference>
  <reference>
    <citation>Shaw E, Scott C, Souhami L, Dinapoli R, Kline R, Loeffler J, Farnan N. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys. 2000 May 1;47(2):291-8.</citation>
    <PMID>10802351</PMID>
  </reference>
  <reference>
    <citation>Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.</citation>
    <PMID>19097774</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2012</study_first_submitted>
  <study_first_submitted_qc>October 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2012</study_first_posted>
  <last_update_submitted>December 7, 2017</last_update_submitted>
  <last_update_submitted_qc>December 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

